| Date Filed | Type | Description |
| 10/11/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 10/11/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/10/2023 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 10/10/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5% stake in Intercept Pharmaceuticals Inc. |
| 10/10/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 09/28/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 09/26/2023 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 11.3% stake in Intercept Pharmaceuticals Inc. |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.5% stake in INTERCEPT PHARMACEUTICALS, INC. |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/24/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/02/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/02/2023 |
8-K
| Quarterly results |
| 02/27/2023 |
8-K
| Other Events Interactive Data |
| 02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0.9% stake in Intercept Pharmaceuticals, Inc. |
| 02/02/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
SC 13G/A
| STATE STREET CORP reports a 7.7% stake in AMEMDED FILING INTERCEPT PHARMACEUTICALS INC |
| 01/25/2023 |
8-K
| Other Events Interactive Data |
| 01/19/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 01/17/2023 |
8-K
| Other Events Interactive Data |
| 01/13/2023 |
SC 13G/A
| MILLENNIUM MANAGEMENT LLC reports a 2.4% stake in INTERCEPT PHARMACEUTICALS, INC. |
| 01/11/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/23/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/09/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/01/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/01/2022 |
8-K
| Quarterly results |
|